Group 1 - The company has initiated trial production for its VC project, indicating progress in its development phase [1] - The company acknowledges that it still needs to undergo a capacity ramp-up process, which is a critical step before full-scale production can be achieved [1]

Core Insights - The chemical pharmaceutical sector experienced a rise of 1.22% on December 17, with Hai Chen Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 3870.28, up 1.19%, while the Shenzhen Component Index closed at 13224.51, up 2.4% [1] Group 1: Stock Performance - Hai Chen Pharmaceutical (300584) closed at 50.55, with a gain of 6.04% and a trading volume of 68,600 shares, amounting to a transaction value of 342 million yuan [1] - Other notable performers included Yahui Pharmaceutical (688176) with a closing price of 10.35, up 5.50%, and ST Renfu (600079) at 18.10, up 4.99% [1] - The overall trading volume and transaction values for various stocks in the sector indicate strong market activity, with ST Renfu recording a trading volume of 1.25 million shares and a transaction value of 2.173 billion yuan [1] Group 2: Fund Flow Analysis - The chemical pharmaceutical sector saw a net outflow of 554 million yuan from institutional investors, while retail investors contributed a net inflow of 799 million yuan [2][3] - The main stocks experiencing significant fund flow included ST Renfu, which had a net inflow of 112 million yuan from institutional investors, while Hai Chen Pharmaceutical saw a net outflow of 18.84 million yuan from retail investors [3] - The overall fund flow dynamics suggest a divergence in investment behavior between institutional and retail investors within the sector [2][3]

Core Viewpoint - Haisun Pharmaceutical has successfully renewed the contract for its product, Landeolol Hydrochloride Injection (50mg), and has newly included the 150mg specification in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operations [1]. Group 1: Stock Performance - As of December 8, 2025, Haisun Pharmaceutical's stock closed at 52.31 yuan, up 2.09% from the previous trading day, with a total market capitalization of 6.277 billion yuan [1]. - The stock opened at 51.36 yuan, reached a high of 52.65 yuan, and a low of 51.31 yuan, with a trading volume of 2.26 billion yuan and a turnover rate of 5.28% [1]. Group 2: Product and Revenue Impact - The product Landeolol Hydrochloride Injection (50mg) has a reimbursement price of 168 yuan per unit, while the 150mg specification is set at 389.55 yuan per unit, with the same payment scope [1]. - The agreement for these products is effective from January 1, 2026, to December 31, 2027 [1]. - In 2024, the sales revenue from the 50mg specification is projected to be 337.77 million yuan, accounting for 67.27% of the company's total revenue [1]. - The renewal of the 50mg specification is not expected to affect performance, while the inclusion of the 150mg specification is anticipated to have a positive long-term impact on operations [1].

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - The company, Hai Chen Pharmaceutical, successfully renewed the contract for its injectable Labetalol Hydrochloride (50mg) and has also included the 150mg version in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The injectable Labetalol Hydrochloride (50mg) has successfully renewed its contract [1] - The injectable Labetalol Hydrochloride (150mg) has been included for the first time in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of Nanjing Haichen Pharmaceutical's injectable Landeolol hydrochloride (50mg) in the National Medical Insurance Directory for 2025, and the first-time inclusion of injectable Landeolol hydrochloride (150mg) [1] Group 1 - Landeolol hydrochloride is a new generation of rapid-acting, ultra-short-acting, highly selective β1 receptor blocker, with a selectivity ratio of approximately 255 times for β1 over β2 receptors, and 8 times more selective than another ultra-short-acting β blocker, Esmolol [2] - The drug has a rapid onset of action (1 to 6 minutes post-administration), a short half-life of about 4 minutes, and minimal negative impact on cardiac hemodynamics and respiratory function [2] - Landeolol is recommended for controlling ventricular rate in acute heart failure patients according to the 2023 National Heart Failure Guidelines, and is also a recommended drug for acute atrial fibrillation in the 2024 Chinese Emergency Management Guidelines [2] Group 2 - The product is projected to achieve sales revenue of 337.77 million yuan in 2024, accounting for 67.27% of the company's total revenue, making it the company's main product [2]

Core Viewpoint - Haicheng Pharmaceutical has successfully renewed the inclusion of its injectable Labetalol Hydrochloride (50mg) and has achieved the first-time inclusion of injectable Labetalol Hydrochloride (150mg) in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released a notification regarding the updated drug catalog for 2025 [1] - The successful renewal of the 50mg formulation indicates continued support for Haicheng Pharmaceutical's product line [1] - The first-time inclusion of the 150mg formulation expands the company's market access and potential revenue streams [1]

证券代码：300584 证券简称：海辰药业 公告编号：2025-054 南京海辰药业股份有限公司 药品分类：选择性β-受体阻滞剂 是否独家品种：是 关于公司注射用盐酸兰地洛尔被纳入国家医保目录的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 2025 年 12 月 7 日，国家医保局、人力资源社会保障部发布了《关于印发< 国家基本医疗保险、生育保险和工伤保险药品目录>以及<商业健康保险创新药 品目录>（2025 年）的通知》（医保发〔2025〕33 号），南京海辰药业股份有 限公司（以下简称"公司"）注射用盐酸兰地洛尔（50mg）续约成功,注射用盐 酸兰地洛尔（150mg）首次纳入《国家基本医疗保险、工伤保险和生育保险药品 目录（2025 年）》（以下简称"国家医保目录"）。具体情况如下： （一）药品名称：注射用盐酸兰地洛尔（50mg） 一、纳入国家医保目录的情况说明 医保支付标准：维持原支付标准，168 元（50mg/支） 限定支付范围：维持原限定支付范围，即限：1、手术过程中发生的下列快 速性心律失常的紧急治疗：心房纤颤、心房扑动、窦性心动过速；2、 ...

Group 1 - The company Hai Chen Pharmaceutical (300584.SZ) is currently preparing for the production launch of its VC project [1] - The lithium sulfide project is undergoing pilot production testing [1]

Core Viewpoint - Haicheng Pharmaceutical (300584) is currently preparing for the production launch of its VC project and is conducting pilot production for its lithium sulfide project [1] Group 1 - The company is in the pre-production preparation phase for its VC project [1] - The lithium sulfide project is undergoing pilot production testing [1]